Moreover a recent systematic review and meta-analysis assessed the impact of different drugs for the treatment of diabetes on the risk of developing dementia, mild cognitive impairment, or cognitive decline highlighting that incretin-based therapies, particularly GLP-1 receptor agonists, were associated with a significant reduction in the risk of cognitive impairment compared to other antidiabetic treatments. Here, GLP1R is linked to dementia.